DK1765397T3 - Inhiberende antistoffer, som binder komplekset af urokinase-type-plasminogenaktivator (uPA) og dens receptor (uPAR) - Google Patents

Inhiberende antistoffer, som binder komplekset af urokinase-type-plasminogenaktivator (uPA) og dens receptor (uPAR)

Info

Publication number: DK1765397T3
Authority: DK; Denmark
Prior art keywords: upar; upa; urokinase; bind; receptor
Prior art date: 2004-05-25

Application number

DK05754219.3T

Other languages

English (en)

Inventor

Graham C Parry

Andrew P Mazar

Original Assignee

Tactic Pharma Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-05-25

Filing date

2005-05-25

Publication date

2013-02-04

2005-05-25 Application filed by Tactic Pharma Llc filed Critical Tactic Pharma Llc

2013-02-04 Application granted granted Critical

2013-02-04 Publication of DK1765397T3 publication Critical patent/DK1765397T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Diabetes (AREA)
Oncology (AREA)
Heart & Thoracic Surgery (AREA)
Molecular Biology (AREA)
Hematology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Endocrinology (AREA)
Ophthalmology & Optometry (AREA)
Genetics & Genomics (AREA)
Cardiology (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Reproductive Health (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Pain & Pain Management (AREA)
Orthopedic Medicine & Surgery (AREA)
Gynecology & Obstetrics (AREA)
Pregnancy & Childbirth (AREA)
Neurology (AREA)
Dermatology (AREA)
Pulmonology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)

DK05754219.3T 2004-05-25 2005-05-25 Inhiberende antistoffer, som binder komplekset af urokinase-type-plasminogenaktivator (uPA) og dens receptor (uPAR) DK1765397T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US57389604P	2004-05-25	2004-05-25
PCT/US2005/018322 WO2005116077A2 (en)	2004-05-25	2005-05-25	LIGANDS BINDING THE COMPLEX OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR (uPA) AND ITS RECEPTOR (uPAR) THAT INHIBIT DOWNSTREAM uPAR INTERACTIONS: IDENTIFICATION AND USE IN DIAGNOSIS OR THERAPY

Publications (1)

Publication Number	Publication Date
DK1765397T3 true DK1765397T3 (da)	2013-02-04

Family

ID=35451457

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK05754219.3T DK1765397T3 (da)	2004-05-25	2005-05-25	Inhiberende antistoffer, som binder komplekset af urokinase-type-plasminogenaktivator (uPA) og dens receptor (uPAR)

Country Status (16)

Country	Link
US (1)	US8101726B2 (da)
EP (1)	EP1765397B1 (da)
JP (1)	JP4890449B2 (da)
KR (1)	KR20070047246A (da)
CN (1)	CN101022830A (da)
AU (1)	AU2005248400A1 (da)
CA (1)	CA2568428C (da)
DK (1)	DK1765397T3 (da)
ES (1)	ES2398221T3 (da)
IL (1)	IL179565A0 (da)
MX (1)	MXPA06013709A (da)
PL (1)	PL1765397T3 (da)
PT (1)	PT1765397E (da)
RU (1)	RU2006145905A (da)
WO (1)	WO2005116077A2 (da)
ZA (1)	ZA200610578B (da)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2007226856A1 (en) *	2006-03-21	2007-09-27	Michael Rynkiewicz	Methods for humanizing antibodies and humanized antibodies made thereby
CN1919874B (zh) *	2006-09-18	2010-09-08	中国人民解放军军事医学科学院生物工程研究所	一种抗尿激酶型纤溶酶激活剂受体的抗体样分子ATF-Fc融合蛋白及其用途
DK2117571T3 (da) *	2006-12-08	2017-05-08	Monopar Therapeutics Inc	Urokinase-type plasminogenaktivatorreceptorepitop
US8815519B2 (en)	2006-12-22	2014-08-26	Hvidovre Hospital	Method for predicting cancer and other diseases
EP2050764A1 (en)	2007-10-15	2009-04-22	sanofi-aventis	Novel polyvalent bispecific antibody format and uses thereof
WO2009061448A2 (en)	2007-11-08	2009-05-14	The General Hospital Corporation	Methods and compositions for the treatment of proteinuric diseases
JP5798037B2 (ja) *	2008-11-06	2015-10-21	ユニバーシティオブマイアミ	蛋白尿腎疾患の病因における可溶性ｕＰＡＲの役割
WO2011038301A2 (en)	2009-09-25	2011-03-31	Xoma Technology Ltd.	Screening methods
WO2012085076A1 (en)	2010-12-22	2012-06-28	Ifom Fondazione Istituto Firc Di Oncologia Molecolare	uPAR-ANTAGONISTS AND USES THEREOF
HUE035281T2 (en)	2011-01-14	2018-05-02	Univ California	Therapeutic antibodies against ror-1 protein and methods for use of same
AR085911A1 (es)	2011-03-16	2013-11-06	Sanofi Sa	Dosis terapeutica segura de una proteina similar a un anticuerpo con region v dual
EP2707055B1 (en)	2011-05-09	2019-10-23	The University of Miami	Reducing soluble urokinase receptor in the circulation
WO2013020898A1 (en)	2011-08-05	2013-02-14	Ifom Fondazione Istituto Firc Di Oncologia Molecolare	Constitutively active upar variants and their use for the generation and isolation of inhibitory antibodies
KR102588702B1 (ko) *	2013-03-15	2023-10-16	더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템	누트린-3a 및 펩티드에 의한 폐 섬유증의 저해
CN105368859B (zh) *	2015-11-25	2019-10-18	王任直	一种嵌合抗原受体hCD87-CAR及载有hCD87-CAR基因结构的慢病毒及质粒及其应用
US10959062B1 (en)	2018-04-19	2021-03-23	Tango Tango, Inc.	System and method for push-to-talk over cellular integration with software defined radio
US10681506B1 (en)	2018-04-19	2020-06-09	Tango Tango, Inc.	System and method for push-to-talk over cellular integration with software defined radio
CN112739367B (zh)	2018-09-10	2025-06-06	莱恩治疗公司	Cav-1蛋白的修饰的肽片段及其在纤维化治疗中的用途
EP3856244A4 (en) *	2018-09-28	2022-07-20	Jochen Reiser	SUPAR AND PREDICTION AND TREATMENT OF ACUTE KIDNEY INJURY
CN115135673A (zh) *	2019-10-28	2022-09-30	莫纳什大学	用于结合纤溶酶的抗体
CN115867570A (zh) *	2020-06-15	2023-03-28	莫诺帕医疗公司	精确放射免疫治疗靶向尿激酶纤溶酶原激活剂受体（uPAR）以治疗严重COVID-19疾病
MX2023011268A (es)	2021-03-24	2023-12-14	Alkermes Inc	Anticuerpos upar y proteínas de fusión con estos.
EP4341296A1 (en) *	2021-05-21	2024-03-27	Northstar Medical Technologies LLC	Urokinase plasminogen activator receptor-targeted radiopharmaceutical
CN117715648A (zh) *	2021-06-11	2024-03-15	纪念斯隆-凯特琳癌症中心	靶向uPAR的抗原识别受体和其用途
US20250197838A1 (en) *	2022-03-24	2025-06-19	The United States Government As Represented By The Department Of Veterans Affairs	Urokinase-type plasminogen activator receptor binding peptides and methods of use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5532132A (en) *	1993-09-28	1996-07-02	President And Fellows Of Harvard University	Method for regulating formation of a complex of plasminogen activator, its receptor and inhibitor
DE10117381A1 (de) *	2001-04-06	2002-10-10	Wilex Biotechnology Gmbh	Herstellung polyklonaler, monospezifischer Antikörper gegen die uPAR-Varianten del4, del5 und del4+5 sowie deren Verwendung für diagnostische und therapeutische Zwecke
AU2003216512A1 (en) *	2002-03-18	2003-10-08	Dyax Corporation	Integrin ligand
DK2117571T3 (da) *	2006-12-08	2017-05-08	Monopar Therapeutics Inc	Urokinase-type plasminogenaktivatorreceptorepitop

2005
- 2005-05-25 KR KR1020067027198A patent/KR20070047246A/ko not_active Withdrawn
- 2005-05-25 AU AU2005248400A patent/AU2005248400A1/en not_active Abandoned
- 2005-05-25 US US11/597,689 patent/US8101726B2/en active Active
- 2005-05-25 ES ES05754219T patent/ES2398221T3/es not_active Expired - Lifetime
- 2005-05-25 CN CNA2005800249140A patent/CN101022830A/zh active Pending
- 2005-05-25 ZA ZA200610578A patent/ZA200610578B/xx unknown
- 2005-05-25 PL PL05754219T patent/PL1765397T3/pl unknown
- 2005-05-25 WO PCT/US2005/018322 patent/WO2005116077A2/en active Search and Examination
- 2005-05-25 CA CA2568428A patent/CA2568428C/en not_active Expired - Lifetime
- 2005-05-25 EP EP05754219A patent/EP1765397B1/en not_active Expired - Lifetime
- 2005-05-25 PT PT57542193T patent/PT1765397E/pt unknown
- 2005-05-25 DK DK05754219.3T patent/DK1765397T3/da active
- 2005-05-25 MX MXPA06013709A patent/MXPA06013709A/es active IP Right Grant
- 2005-05-25 RU RU2006145905/13A patent/RU2006145905A/ru not_active Application Discontinuation
- 2005-05-25 JP JP2007515288A patent/JP4890449B2/ja not_active Expired - Lifetime
2006
- 2006-11-23 IL IL179565A patent/IL179565A0/en unknown

Also Published As

Publication number	Publication date
CA2568428C (en)	2020-12-29
RU2006145905A (ru)	2008-06-27
PT1765397E (pt)	2013-02-04
IL179565A0 (en)	2007-05-15
MXPA06013709A (es)	2008-01-16
ZA200610578B (en)	2009-09-30
JP4890449B2 (ja)	2012-03-07
WO2005116077A3 (en)	2005-12-29
EP1765397B1 (en)	2012-10-24
US8101726B2 (en)	2012-01-24
US20090180952A1 (en)	2009-07-16
KR20070047246A (ko)	2007-05-04
PL1765397T3 (pl)	2013-04-30
ES2398221T3 (es)	2013-03-14
AU2005248400A1 (en)	2005-12-08
EP1765397A2 (en)	2007-03-28
JP2008509086A (ja)	2008-03-27
EP1765397A4 (en)	2009-05-13
CA2568428A1 (en)	2005-12-08
CN101022830A (zh)	2007-08-22
WO2005116077A2 (en)	2005-12-08

Publication	Publication Date	Title
DK1765397T3 (da)	2013-02-04	Inhiberende antistoffer, som binder komplekset af urokinase-type-plasminogenaktivator (uPA) og dens receptor (uPAR)
HUS2300026I1 (hu)	2023-09-28	Anti-CTLA-4 ellenanyag készítmények
NO20190202A1 (no)	2008-05-19	Anvendelse av anti-CGRP antagonist antistoff
NO20083147L (no)	2008-09-16	Anti-OX40L-antistoffer og fremgangsmater for anvendelse av disse
EP2117571A4 (en)	2010-08-04	PLASMINOGEN ACTIVATOR RECEPTOR EPITOP OF THE UROKINASE TYPE, MONOCLONAL ANTIBODIES, AND APPLICATIONS METHOD THEREBY
NO20083397L (no)	2008-10-02	Anti-EphB4-antistoffer og fremgangsmater for anvendelse av disse
DK2390267T3 (da)	2013-08-26	Stabile og opløselige antistoffer, der hæmmer TNF(alfa)
DK1945666T3 (da)	2013-07-01	Antistoffer med forøget antistofafhængig cellulær cytotoksicitetsaktivitet, fremgangsmåder til fremstilling af disse og anvendelse heraf
DK3421498T3 (da)	2022-02-14	Monoklonale antistoffer mod claudin-18 til behandling af cancer
IL237168A0 (en)	2015-03-31	Monoclonal antibodies selective for expressing amyloid, preparations, mixtures and their use
PL2177537T3 (pl)	2012-06-29	Przeciwciała przeciw MadCAM
DE602006017373D1 (de)	2010-11-18	Madcam-antikörper
NO20080692L (no)	2008-04-03	SP35 antistoffer og anvendelse derav
DK1723128T3 (da)	2013-02-18	Heteroarylurinstoffer og deres anvendelse som glucokinaseaktivatorer
NO20052496D0 (no)	2005-05-24	Selekterte CGRP antagonister, fremgangsmater for fremstilling derav og anvendelse derav som medikamenter.
DK3530673T3 (da)	2022-04-19	Humaniserede anti-beta7-antagonister og anvendelser deraf
DK1773885T3 (da)	2010-08-16	Humaniserede anti-c-met-antagonister
NO20053101D0 (no)	2005-06-24	Kimaere og humaniserte antistoffer motalfa-5beta-1 integrin som modulerer angiogenese.
WO2008002472A3 (en)	2008-03-13	Systematic evaluation of sequence and activity relationships using site evaluation libraries for engineering multiple properties
SI1960432T1 (sl)	2016-08-31	Protitelo proci icam, ki inducira apoptozo
NL1028927A1 (nl)	2005-11-03	Nieuwe verbindingen.
NO20083593L (no)	2008-10-17	Anti-EphrinB2-antistoffer og fremgangsmater for anvendelse av disse
DK1907854T3 (da)	2011-07-11	Monoklonale antistoffer, hybridomcellelinjer, fremgangsmåder og kits til detektion af phytase
DK1874765T3 (da)	2012-06-18	Ureaderivater, fremgangsmåder til fremstilling af disse og anvendelser deraf
NO20054709D0 (no)	2005-10-13	Sammenfoyningssystem og anvendelse av dette